Literature DB >> 9230852

Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome. Why no magic bullets?

A E Baue1.   

Abstract

The concept of multiple organ failure and related abnormalities was first developed in the 1970s. Multiple organ failure became evident when the support systems in intensive care units were able to keep patients alive long enough for multiple organ problems to develop in them. The high mortality of patients with multiple organ failure provided a focus for the problems that ultimately led to death for many patients in the intensive care unit. The frequency of infection, sepsis, or inflammation in producing multiple organ failure led to clinical trials of so-called magic bullets for the treatment of patients with sepsis. These trials have had either limited success or negative results, despite considerable evidence for efficacy or protection by such agents in experimental animals and in studies of normal human volunteers. I believe a major reason for these negative results has been the use of general entry criteria for the trials rather than the treatment of specific diseases or injuries.

Entities:  

Mesh:

Year:  1997        PMID: 9230852     DOI: 10.1001/archsurg.1997.01430310017002

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  19 in total

1.  Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: role of adrenomedullin and adrenomedullin binding protein-1.

Authors:  Shaolong Yang; Mian Zhou; Irshad H Chaudry; Ping Wang
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

Review 2.  Management of peritonitis in the critically ill patient.

Authors:  Carlos A Ordoñez; Juan Carlos Puyana
Journal:  Surg Clin North Am       Date:  2006-12       Impact factor: 2.741

3.  Melanocortins protect against multiple organ dysfunction syndrome in mice.

Authors:  Alessandra Bitto; Francesca Polito; Domenica Altavilla; Natasha Irrera; Daniela Giuliani; Alessandra Ottani; Letteria Minutoli; Luca Spaccapelo; Maria Galantucci; Renzo Lodi; Giuseppe Guzzo; Salvatore Guarini; Francesco Squadrito
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Sequential changes in the metabolic response in severely septic patients during the first 23 days after the onset of peritonitis.

Authors:  L D Plank; A B Connolly; G L Hill
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

Review 5.  The future of murine sepsis and trauma research models.

Authors:  Philip A Efron; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer
Journal:  J Leukoc Biol       Date:  2015-06-01       Impact factor: 4.962

6.  Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage.

Authors:  D Giuliani; C Mioni; C Bazzani; D Zaffe; A R Botticelli; S Capolongo; A Sabba; M Galantucci; A Iannone; P Grieco; E Novellino; G Colombo; A Tomasi; A Catania; S Guarini
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

7.  Role of gut-lymph factors in the induction of burn-induced and trauma-shock-induced acute heart failure.

Authors:  Marlon A Lee; Atsuko Yatani; Justin T Sambol; Edwin A Deitch
Journal:  Int J Clin Exp Med       Date:  2008-03-31

8.  Adrenomedullin and adrenomedullin binding protein-1 attenuate vascular endothelial cell apoptosis in sepsis.

Authors:  Mian Zhou; H Hank Simms; Ping Wang
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

9.  Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria.

Authors:  Robert J Feezor; Caroline Oberholzer; Henry V Baker; Daniela Novick; Menachem Rubinstein; Lyle L Moldawer; John Pribble; Sonia Souza; Charles A Dinarello; Wolfgang Ertel; Andreas Oberholzer
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  The potential role of transcription factor aryl hydrocarbon receptor in downregulation of hepatic cytochrome P-450 during sepsis.

Authors:  Mian Zhou; Subir R Maitra; Ping Wang
Journal:  Int J Mol Med       Date:  2008-04       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.